Dose-escalating ruxolitinib for refractory hemophagocytic lymphohistiocytosis

BACKGROUND: Hemophagocytic lymphohistiocytosis (HLH) is a severe disorder characterized by excessive secretion of cytokines. Even with the recommended HLH-94/2004 regimen, over 30% of patients remain refractory to frontline therapy or relapse after an initial response, leading to poor clinical outco...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Yue, Li, Xiaoli, He, Xuefeng, Zhou, Fei, Du, Feng, Wang, Ziyan, Chen, Suning, Wu, Depei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339381/
https://www.ncbi.nlm.nih.gov/pubmed/37457729
http://dx.doi.org/10.3389/fimmu.2023.1211655

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339381/
https://www.ncbi.nlm.nih.gov/pubmed/37457729
http://dx.doi.org/10.3389/fimmu.2023.1211655

Ejemplares similares